FDA Cancer Drug Approvals in 2017

Slideshow

This slide show highlights some of this year’s FDA approvals of cancer treatments, including new therapies and indications for breast cancer, lung cancer, and various blood cancers, as well as the first approval based not on disease site but by tumor marker.

Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 3 experts on CML
Related Content
The safety profile of nivolumab/relatlimab/chemotherapy in RELATIVITY-104 was comparable with prior reports of each individual agent.

Clinical Benefit Improves With Relatlimab Combo in Recurrent NSCLC

Darlene Dobkowski, MA
September 14th 2024
Article

The safety profile of nivolumab/relatlimab/chemotherapy in RELATIVITY-104 was comparable with prior reports of each individual agent.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Neoadjuvant endocrine therapy or paclitaxel with trastuzumab/pertuzumab elicited significant survival in HR-positive, HER2-positive early breast cancer.

Neoadjuvant ET And De-Escalated Chemotherapy Lead to ‘Exceptionally Excellent’ Survival in HR+/HER+ Early Breast Cancer

Alex Biese
September 14th 2024
Article

Neoadjuvant endocrine therapy or paclitaxel with trastuzumab/pertuzumab elicited significant survival in HR-positive, HER2-positive early breast cancer.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Amivantamab plus chemotherapy also improved time to symptomatic progression among patients enrolled on the MARIPOSA-2 trial.

Amivantamab/Chemo Shows Sustained OS in Advanced EGFR+ NSCLC

Darlene Dobkowski, MA
September 14th 2024
Article

Amivantamab plus chemotherapy also improved time to symptomatic progression among patients enrolled on the MARIPOSA-2 trial.

Belrestotug/Dostarlimab Improves ORR in PD-L1–High NSCLC

Belrestotug/Dostarlimab Improves ORR in PD-L1–High NSCLC

Kristi Rosa
September 14th 2024
Article

Data from the GALAXIES-Lung 201 trial found efficacy improvement in patients with advanced NSCLC.